Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Dan was pushed out because he was greedy and unethical and a terrible steward of investor capital, as proven by the +40% shareholder value destroyed on his watch."
FBG; I think it's worse than that because,
during that time the many competitive companies made significant advances ( there weren't many when i first bought in); and
Our IP continued to age, along with the "time value" of our investments.
Meanwhile innumerable cancer victims we might have helped, up and died.
Hi Masters;
I foolishly bought at the peak, a bit soused and late at night...Charmed by the story again. I didn't commit a whole lot though.
The enthusiasm that fueled the peak is apt to wind down unless there are some wonderful clinical trials reports or "I survived my deadly cancer thanks to Clovis" type publicity.
The science remains very tasty.
I see PACB is up an appealing 11% however, for some reason.
Get them to do that again 5 more times so i can break even please!
They've got a promising tech ( CAR-T) involving tailoring immune cells to attack cancers..A lot like KITE's .Good clinical trial results propelled them.
Typically, the price on these stocks sinks between positive news announcements....Assuming they are positive. Cancer cures face long odds.
After 20 years of bureaucracy and histrionics..finally...YES!
Folks eat GM corn, soy, etc daily with only the occasional twitch.
What they should be paying attention to is the specifics of the genetic modification.
It's eating more Roundup and Bt toxins and their breakdown products that bother me. Not to mention the huge onslaught of bio-active chemicals.
Fast salmon sans antibiotic resistant bacteria and fungicides, seems just nifty.
I got stock when XON spun them off and i'll keep it.
Well Mr Masters: I'm in both NVTA and NVDA. The former having more in common with PACB which are both early and risky....But..."If all goes as planned"
That also applies to Clovis but you are probably right.
I'm a sucker for a good story and don't pay enough attention to management.
Indeed: a very long wait and i'm getting old faster and faster.
Hey, hey! Up 20% on great earnings!
That oughta get your attention.
Raja, to quote you, so it MUST be right...
"He could not deliver" (DOC).
And i don't have all that much faith in the interim CEO either.
I sure have lost a pile of $ here over the years.
Feel stupid for not having sold at the peaks, in retrospect.
Watch me change my tune when/if we get EU approval.
That satisfies the present study status but does not explain why it took so long to get there that the patent is so long since expired.
Unless i'm misunderstanding this stuff entirely ( wouldn't be the first time).
My guess at the time was that he wanted someone else to carry to cost of the ph 3 trials and was trying to arrange that.
Also, so many promising onco drug candidates that looked good early on,
falter or fail in Ph 3, that the risk might seem unacceptable to a CEO who had a nice cushy position that could be sustained with more inexpensive, early stage trials.
I suspect the same thing was even more likely at AVXL.
Hi Raja:
He gets credit for reviving the company, no doubt.
If he'd continued apace, his self serving actions would have been justified.
With the enormous potential income from our drug candidates,
why do folks want a buy out?
Given that owning small bios is something of a gamble that we accept;
it seems terribly shortsighted to want a buyout....
Well, unless you are a day trader i guess.
Encouraging indeed.
Now we need a dozen more accounts like Novagene.
But respectfully Masters, now isn't the time to buy more ,given the surge in PPS and given you're already overcommitment to PACB...Time to spread your bets instead.
There was a hilarious, curmudgeonly and enthusiastically vulgar older woman investor to the boards some time back. She was a very canny, if unconventional investor and last heard was about to buy another apartment building with her winnings. I suspect she vanished because of board censorship. Too bad.
One of her techniques was to sell whenever a volatile stock made a big surge unless the news was apt to materially and proportionately enhance the stocks value in the long run. Then, in a month or 3, when things had settled back down, she'd buy back in.
Forgetting her example, i recently read some promising articles re Clovis and trotted out and bought some, despite the recent PPS run up. Needless to say, it's been drifting down ever since.
More extension on the offer and they say they'll keep doing it.
Same measly offer.
Meanwhile, the SP has exceeded the offer amount by a bit and the value of the company continues to rise apace.
Again; if we go along with the sale, we'll be stuck with Qualcon's slow growth instead of the rocket we own.
Please urge management to back out of the deal.
I understand that doing science takes time. I'm alive because of a cancer trial.
But explain how it could be possible that we have had the osteo-sarcoma construct for so very many years with nothing to show for it?
How many years please Mpre?
Good point Tinfoillurker.
Let's replace them too...grin.
A big concern is how do we find somebody a whole lot better?
Not just that Ignatius:
We've had these excellent constructs a very long time.
Only now do we have a PH3 trial and that's rather small ,will resolve slowly and is limited in ambition
.Etc.
DOC also demonstrated a lack of effective strategy in pushing our best drug candidates through the necessary series of clinical trials to achieve FDA approval and get to market in the minimum amount of time.
Instead he spent time and money on himself and various presentations as well as assorted diversions, fruitless "deals" and distractions.
He largely ignored the time value of our investments while cancer victims continue to die.
Not so surprising....One expects a fairly high failure rate in clinical trials,
though if they are just saving face, it'd be disheartening.
Let's see here; We've got a pipeline full of promising candidates and a multitude of trials in progress....Revenues are up by 30 some %....
and the PPS drops 3.5%....Huh?
I'm in for the long haul. Looks very good.
Presently we are up about 1%...Hardly"Hammered". The sky ISN'T falling!
Dizzle; you seem to be a short and a day trader ( most lose $ in the long run),
so what you have to say is pretty meaningless from my long perspective.
BLRX's drug candidates look pretty good. If they keep proving out in clinical trials we should profit very nicely.
Assuming they are still progressing with the clinical trial(s) , then they aren't entirely rudderless.
Most small clinical stage bios wallow around between trials results.
Looks like we are acquiring 2 smaller genetics testing companies and selling some stock in a private placement.
We remain the fastest growing company in our field.
Seems about DW;
Little cash flow negative companies with a grim history like ours tend to be a yoyo ride at best...Um...Yipee!!! ?
Looking back at the 5 year chart...i feel stupid for not having bought a whole lot more just after the big short attack...Would have reaped a 5 fold profit..
Gee Jack;
You are sounding nearly optimistic of late.
Kinda has me worried!
DW:
" but always find myself wondering, how in the world did it go the direction it just went. Perception? Who the heck knows on any given day what they will be? "
Basically, when i bought in, oil was $100/bbl and alarmists were crowing "peak oil". Diesel was really high.
Then the prospect of NG diesels that could burn that cheap fuel looked very appealing.
Wprt was bragging about it's new advanced technology with further developments on the way. The NG fueling infrastructure was being built out and so on.
Then came fracking and extensive international oil discoveries and our big price advantage diminished greatly....and so on...downhill from there.
Fire, i didn't see any investor's section or a pipeline progress listing during my quick look around their website.
Where would i find that stuff please.
I couldn't wait for AVXL to hit the big time anymore either,
that's why i finally sold all my stock in it.
They were all hype and hope so far as i could see.
When we see a successful, well designed Ph 3 trial, i'll consider getting back in.
CLVS, on the other hand is up 5.6% on no news i can see.
We are pretty much dead in the water
until we get well designed, strategically optimal,
end stage clinical trials working through completion.
We have one, i believe, and it isn't really optimal ( except for cost).
Those phase 3 trials are where the proverbial rubber hits the road,
and the proof in the pudding for a clinical stage bio like ourselves.
We need to focus on the best bets and dump all our resources
into pushing the forward.
Unless the EU application comes through,
our SP will languish until we have good ph 3 results to show.
Agreed Easymoneyman:
We've seen a wide swath of both up and down PPSs,
and it's reasonable to presume we'll see more of both.
If we have the SOC for cervical cancer alone,
( and there's an excellent chance we have much more than just that)
then $35 is a pathetic price to settle for.
Agreed Hov;
We tend to snivel or exult in unison.
The dog's cancer deaths are tragic.
The children's deaths to the same cancers are worse.
The same genetic error shows up in other cancers as well.
Isn't this our oldest construct?
Why aren't we completing a Ph 3 trial on this yet?
Batermere;
We're not gonna see that kinda offer in a buy out, respectfully. That's just wishful thinking.
What we need now that DOC is gone, is a brilliant, experienced and aggressive CEO that can push our excellent IP to market in a strategically expedient manner.
The Temp CEO has a history of pumping companies up and selling them.
But we have the production facility, we should be close to EU approval, we still have a juicy pile of lysteria constructs and some new stuff in the mill.
A competent CEO might kick some butt on the languishing osteo-sarcoma agreement too, or take the construct to somebody who will get it approved and on the market...And perhaps the same applies to our other "deals".
We have clinical trials showing splendid results that are unequalled across the industry with very few exceptions....And folks continuing dying in large numbers that we have the potential to help.
Giving up and feebly selling out with a whimper , is defeatist and unacceptable!
Us old longs have stuck with ADXS through too much crap, for too long, to just roll over and play dead!
Apologies Zig;
I bought embarrassingly early before the RS if i recall rightly ( been a long time and my memory has begun to deteriorate).
Good luck to you!
Hello again Xena;
AVXL is debt free and that's admirable, but...
1. They are also product free,
2. IP has a diminishing time value.
3. Debt is cheap right now.
4. huge numbers of people are dying of ALZ!
5.The presumed object here isn't simply to stay in business as long as possible,
it's to get our products out on the market, cure folks and make money.
Johnny:
Given that we have enough $ to keep operating and the fusidic acid study in process; would it be reasonable to keep slugging forward and see if we can get a drug approved?
I'm assuming that the first rejection was, um, educational and the same mistake can be avoided.
We suffered a massive disappointment, but we ain't dead yet.
Hey Masters:
Agreed, the PPS hurts and probably will for a while.
OTH you didn't buy into CEMP like i did and Really eat it.
It's why we spread our bets in small bios.
We need to find out what the problem is and fix it!
The safety threat is unlikely to be worse than the harsh old last resort drugs they are dragging out in desperation now.